The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty

Bone Joint J. 2020 Jul;102-B(7):950-958. doi: 10.1302/0301-620X.102B7.BJJ-2019-0105.R2.

Abstract

Aims: To assess how the cost-effectiveness of total hip arthroplasty (THA) and total knee arthroplasty (TKA) varies with age, sex, and preoperative Oxford Hip or Knee Score (OHS/OKS); and to identify the patient groups for whom THA/TKA is cost-effective.

Methods: We conducted a cost-effectiveness analysis using a Markov model from a United Kingdom NHS perspective, informed by published analyses of patient-level data. We assessed the cost-effectiveness of THA and TKA in adults with hip or knee osteoarthritis compared with having no arthroplasty surgery during the ten-year time horizon.

Results: THA and TKA cost < £7,000 per quality-adjusted life-year (QALY) gained at all preoperative scores below the absolute referral thresholds calculated previously (40 for OHS and 41 for OKS). Furthermore, THA cost < £20,000/QALY for patients with OHS of ≤ 45, while TKA was cost-effective for patients with OKS of ≤ 43, since the small improvements in quality of life outweighed the cost of surgery and any subsequent revisions. Probabilistic and one-way sensitivity analyses demonstrated that there is little uncertainty around the conclusions.

Conclusion: If society is willing to pay £20,000 per QALY gained, THA and TKA are cost-effective for nearly all patients who currently undergo surgery, including all patients at and above our calculated absolute referral thresholds. Cite this article: Bone Joint J 2020;102-B(7):950-958.

Keywords: Arthroplasty; Cost-utility analysis; Economic evaluation; Hip; Joint arthroplasty; Knee; Osteoarthritis.

MeSH terms

  • Aged
  • Arthroplasty, Replacement, Hip / economics*
  • Arthroplasty, Replacement, Knee / economics*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Male
  • Markov Chains
  • Middle Aged
  • Osteoarthritis, Hip / surgery
  • Osteoarthritis, Knee / surgery
  • Patient Reported Outcome Measures*
  • Probability
  • Quality-Adjusted Life Years*
  • Referral and Consultation*
  • United Kingdom